Medtronic, a global leader in healthcare technology, has announced three groundbreaking milestones that significantly expand diabetes management options for millions of Americans living with type 1 and insulin-requiring type 2 diabetes. These developments represent a major advancement in automated insulin delivery systems, offering unprecedented choice, flexibility, and access to life-changing diabetes technology.
Medicare Coverage Now Available for Advanced Diabetes Technology
In a significant development for older Americans with diabetes, Medicare and Medicare Advantage beneficiaries can now access the MiniMed™ 780G system integrated with the Instinct sensor manufactured by Abbott. This expansion provides Medicare users with multiple sensor options, including the Instinct sensor alongside the previously available Simplera Sync™ and Guardian™ 4 sensors.
The Instinct sensor offers exceptional convenience with its small, thin design that can be worn discreetly for up to 15 days. This extended wear time reduces the frequency of sensor changes, minimizing disruption to daily routines while maintaining continuous glucose monitoring accuracy.
“These milestones reflect our unwavering commitment to expanding access and giving individuals living with diabetes more choice in how they manage their condition,” said Que Dallara, EVP & president of Medtronic Diabetes. “By broadening sensor and insulin options for the MiniMed™ 780G system, we’re empowering more people to benefit from automated insulin delivery that supports easier mealtimes, greater flexibility, and more confident diabetes management—making everyday life a bit easier.”
Streamlined Medicare Process for Eligible Patients
Medicare customers who previously placed orders for the MiniMed™ 780G system with the Instinct sensor will now advance through the standard Medicare billing and fulfillment process, subject to individual eligibility and insurance requirements. Medtronic Diabetes is working closely with distributor partners to ensure readiness and timely shipment for all eligible customers, streamlining access to this advanced diabetes management technology.
Ultra Rapid-Acting Insulin Options Enhance Treatment Flexibility
The FDA has cleared the MiniMed™ 780G system for use with ultra rapid-acting insulins Fiasp and Lyumjev, providing people living with type 1 and insulin-requiring type 2 diabetes with enhanced personalization in their therapy regimen.
Ultra rapid-acting insulin more closely mimics the body’s natural insulin response, particularly during mealtimes. Its faster onset helps reduce the impact of late or missed meal doses, allowing the insulin to “catch up” more effectively when mealtime boluses are delayed or underestimated.
Meal Detection Technology Reduces Daily Burden
When paired with the MiniMed™ 780G system’s unique Meal Detection™ technology, these insulin options significantly reduce the burden and pressure around mealtimes when carbohydrate counts aren’t exact or meal doses are sometimes missed or delayed. This combination allows clinicians and individuals to select the insulin that best matches their physiology and lifestyle, supporting more customized therapy and potentially improving overall glucose outcomes.
The automated system responds to glucose changes every five minutes, automatically adjusting insulin delivery to help maintain stable glucose control. This means fewer dangerous highs and lows, less daily decision-making stress, and a more streamlined approach to staying within recommended glucose ranges.
Type 2 Diabetes Patients Gain Access to Advanced Automated System
The FDA has cleared the SmartGuard™ algorithm as an interoperable automated glycemic controller (iAGC) and the MiniMed™ 780G insulin pump as an alternate controller enabled (ACE) device for insulin-requiring type 2 diabetes, enabling seamless integration with the Instinct sensor manufactured by Abbott.
People living with insulin-requiring type 2 diabetes face a demanding daily routine that impacts both physical and emotional well-being—from multiple daily injections to constant meal planning and vigilant glucose monitoring. The MiniMed™ 780G system helps lighten this daily load by automatically adjusting insulin delivery every five minutes and managing missed or underestimated meal boluses.
Expert Clinical Perspective on Technology Benefits
“Bringing together the Instinct sensor, made by Abbott, with the well-established algorithm of the MiniMed™ 780G system makes for an extremely effective combination,” said Dr. Anders Carlson, Associate Executive Director of the International Diabetes Center in Minneapolis, Minnesota. “I think anyone who requires insulin therapy to manage their diabetes, whether it’s type 1 or type 2 diabetes, can benefit from automated insulin delivery. I’m thrilled that the MiniMed™ 780G system with the Instinct sensor is now cleared for this population, so that more people living with type 2 diabetes will get access to this life-changing technology improving their day-to-day experience in managing their diabetes.”
Comprehensive Sensor Options for All Diabetes Types
The MiniMed™ 780G system for insulin-requiring type 2 diabetes can now be ordered with the Instinct sensor along with the Guardian™ 4 and Simplera Sync™ sensors. The Instinct sensor, made by Abbott, is currently available for type 1 diabetes and represents the world’s smallest and thinnest integrated continuous glucose monitor, offering up to 15 days of discreet wear.
This expanded access means more individuals can benefit from automated insulin delivery technology that reduces the mental and physical burden of constant diabetes management, allowing them to focus on living their lives with greater confidence and freedom.
Medtronic, a global leader in healthcare technology, has announced three groundbreaking milestones that significantly expand diabetes management options for millions of Americans living with type 1 and insulin-requiring type 2 diabetes. These developments represent a major advancement in automated insulin delivery systems, offering unprecedented choice, flexibility, and access to life-changing diabetes technology.
Medicare Coverage Now Available for Advanced Diabetes Technology
In a significant development for older Americans with diabetes, Medicare and Medicare Advantage beneficiaries can now access the MiniMed™ 780G system integrated with the Instinct sensor manufactured by Abbott. This expansion provides Medicare users with multiple sensor options, including the Instinct sensor alongside the previously available Simplera Sync™ and Guardian™ 4 sensors.
The Instinct sensor offers exceptional convenience with its small, thin design that can be worn discreetly for up to 15 days. This extended wear time reduces the frequency of sensor changes, minimizing disruption to daily routines while maintaining continuous glucose monitoring accuracy.
“These milestones reflect our unwavering commitment to expanding access and giving individuals living with diabetes more choice in how they manage their condition,” said Que Dallara, EVP & president of Medtronic Diabetes. “By broadening sensor and insulin options for the MiniMed™ 780G system, we’re empowering more people to benefit from automated insulin delivery that supports easier mealtimes, greater flexibility, and more confident diabetes management—making everyday life a bit easier.”
Streamlined Medicare Process for Eligible Patients
Medicare customers who previously placed orders for the MiniMed™ 780G system with the Instinct sensor will now advance through the standard Medicare billing and fulfillment process, subject to individual eligibility and insurance requirements. Medtronic Diabetes is working closely with distributor partners to ensure readiness and timely shipment for all eligible customers, streamlining access to this advanced diabetes management technology.
Ultra Rapid-Acting Insulin Options Enhance Treatment Flexibility
The FDA has cleared the MiniMed™ 780G system for use with ultra rapid-acting insulins Fiasp and Lyumjev, providing people living with type 1 and insulin-requiring type 2 diabetes with enhanced personalization in their therapy regimen.
Ultra rapid-acting insulin more closely mimics the body’s natural insulin response, particularly during mealtimes. Its faster onset helps reduce the impact of late or missed meal doses, allowing the insulin to “catch up” more effectively when mealtime boluses are delayed or underestimated.
Meal Detection Technology Reduces Daily Burden
When paired with the MiniMed™ 780G system’s unique Meal Detection™ technology, these insulin options significantly reduce the burden and pressure around mealtimes when carbohydrate counts aren’t exact or meal doses are sometimes missed or delayed. This combination allows clinicians and individuals to select the insulin that best matches their physiology and lifestyle, supporting more customized therapy and potentially improving overall glucose outcomes.
The automated system responds to glucose changes every five minutes, automatically adjusting insulin delivery to help maintain stable glucose control. This means fewer dangerous highs and lows, less daily decision-making stress, and a more streamlined approach to staying within recommended glucose ranges.
Type 2 Diabetes Patients Gain Access to Advanced Automated System
The FDA has cleared the SmartGuard™ algorithm as an interoperable automated glycemic controller (iAGC) and the MiniMed™ 780G insulin pump as an alternate controller enabled (ACE) device for insulin-requiring type 2 diabetes, enabling seamless integration with the Instinct sensor manufactured by Abbott.
People living with insulin-requiring type 2 diabetes face a demanding daily routine that impacts both physical and emotional well-being—from multiple daily injections to constant meal planning and vigilant glucose monitoring. The MiniMed™ 780G system helps lighten this daily load by automatically adjusting insulin delivery every five minutes and managing missed or underestimated meal boluses.
Expert Clinical Perspective on Technology Benefits
“Bringing together the Instinct sensor, made by Abbott, with the well-established algorithm of the MiniMed™ 780G system makes for an extremely effective combination,” said Dr. Anders Carlson, Associate Executive Director of the International Diabetes Center in Minneapolis, Minnesota. “I think anyone who requires insulin therapy to manage their diabetes, whether it’s type 1 or type 2 diabetes, can benefit from automated insulin delivery. I’m thrilled that the MiniMed™ 780G system with the Instinct sensor is now cleared for this population, so that more people living with type 2 diabetes will get access to this life-changing technology improving their day-to-day experience in managing their diabetes.”
Comprehensive Sensor Options for All Diabetes Types
The MiniMed™ 780G system for insulin-requiring type 2 diabetes can now be ordered with the Instinct sensor along with the Guardian™ 4 and Simplera Sync™ sensors. The Instinct sensor, made by Abbott, is currently available for type 1 diabetes and represents the world’s smallest and thinnest integrated continuous glucose monitor, offering up to 15 days of discreet wear.
This expanded access means more individuals can benefit from automated insulin delivery technology that reduces the mental and physical burden of constant diabetes management, allowing them to focus on living their lives with greater confidence and freedom.
Discover the latest GovHealth news updates with a single click. Follow DistilINFO GovHealth and stay ahead with updates. Join our community today!
